Multicentre, open-label post-marketing follow-up observational study to evaluate the efficacy/tolerability of the Philips BlueTouch Pain Relief Patch in the daily routine treatment of back pai

Recruiting

Conditions: ocalized unspecific pain of the upper or lower back

Registration Number: DRKS00005707

Lead Sponsor: Philips Consumer Lifestyle

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 1000

Inclusion Criteria

Patient age =18 years
Patient is able and willing to understand a written informed consent
Patient suffers from back pain
Patient is able to comply with the study characteristics and to fulfill its requirements, according to the investigator's evaluation

Exclusion Criteria

Patient is currently or was within the previous 4 weeks enrolled in an interventional clinical trial

Patient is actually suffering from conditions and illnesses that might interfere with the trial purpose, according to the investigator's evaluation

Patient has a history of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) that could limit the subject's ability to comply with trial procedures

Patient has insufficient knowledge of the German language to understand the Informed Consent Form and/or trial questionnaires

Patient is/was involved in the planning and conduct of the trial (applies to either Philips staff, staff participating at the trial site or staff of the logistics CRO)

Patient suffers from any condition or illness as listed in the contraindications section of the BlueTouch Pain Relief Patch user manual

Patient has used the Philips BlueTouch Pain Relief Patch before

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome on efficacy and tolerability:<br>Queries based on two verbal rating scales in the physician's interim documentation (after 1 week of therapy) as well as in the physician's end documentation (after 2 weeks of therapy) compared to the previous non-drug or drug treatments.

Secondary Outcome Measures